

## Gador S.A.

[View the current Gador S.A. Page on BioPortfolio.com](http://www.bioportfolio.com/biocorporate/23228-Gador+S.A..html)

(<http://www.bioportfolio.com/biocorporate/23228-Gador+S.A..html>)

### Contact Details:

**Darwin 429**  
**Buenos Aires**

Tel: (54-11) 4858-9000

Fax:

Email: [info@gador.com.ar](mailto:info@gador.com.ar)

**1414**

**Argentina**

Internet and e-mail are magic words in communication. Recombinant protein, monoclonal antibody and gene therapy are a few expressions which witness the progress of health sciences. True to its mission, Gador has actively participated in bringing new knowledge to daily life for more than half a century. By means of Gador's own research, high-quality and price-conscious drugs have been developed. Today, we continue to work with the same will, constantly devoted to the improvement of health. We are pleased to convey through the Internet detailed and objective data about Gador and its line of products. It reflects the image of a company sensitive to changes and aimed at the future, which strengthens the confidence among professionals and patients. With a help of the Internet we will navigate through this information together.

### BioNews Results for Gador S.A.



- [Genetic Polymorphism and Major Depression: New Theories](#)  
*Consultant Live: Nov 15 2009 7:17PM Matching: s*
- [A pandemic response to a disease of predominantly seasonal intensity - 16 November 2009](#)  
*The Medical Journal of Australia: Nov 15 2009 3:10PM Matching: s*
- [Schmid M, Egli K, Martin BW, Bauer G. Health promotion in primary care: evaluation of a systematic procedure a](#)  
*Swiss Medical Weekly: Nov 14 2009 10:06PM Matching: s*
- [Cook S, Windecker S. Revascularisation of coronary artery disease in patients with diabetes mellitus \[654\]](#)  
*Swiss Medical Weekly: Nov 14 2009 10:07PM Matching: s*
- [Apoptosis Cell Biology: Scientists at University of Lausanne, Center for Integrative Genomics detail research in apoptosis cell biology](#)  
*NewsRX: Nov 14 2009 6:48AM Matching: s*
- [Polymyxin B and colistimethate are comparable as to efficacy and renal toxicity](#)

- DiagnosticMicrobiology and Infectious Disease: Nov 13 2009 4:14PM Matching: s*
- [Findings on the use of Traumeel S in children with mucositis undergoing SCT presented](#)  
*News-Medical.Net: Nov 13 2009 11:48AM Matching: s*
  - [Ng, S. B. et al. Nature Genetics Selective sequencing solves a genetic mystery](#)  
*Nature: Nov 13 2009 10:01PM Matching: s*
  - [Boehringer Ingelheim Corporation's Desire Drug May Prove Sex Really Is All in Her Head](#)  
*BioSpace: Nov 13 2009 5:50PM Matching: s*
  - [Mechanical ventilation damages lungs, says scientist](#)  
*News-Medical.Net: Nov 13 2009 12:22PM Matching: s*
  - [Novartis Corporation \(NVS\) \(JOBS\) Puts R&D Activities in India on Hold](#)  
*BioSpace: Nov 13 2009 1:26AM Matching: s*
  - [Altus Pharmaceuticals Inc. \(ALTU\) Files for Chapter 7 Bankruptcy](#)  
*BioSpace: Nov 13 2009 1:24AM Matching: s*
  - [/C O R R E C T I O N -- Neuro-Med.net/](#)  
*Freshnews.com: Nov 13 2009 12:28AM Matching: s*
  - [Mechanical ventilation for patients with lung damage don't always work as planned](#)  
*Genetic Engineering News: Nov 12 2009 5:22PM Matching: s*
  - [HL7 Announces Industry's First Electronic Health Record System \(EHR-S\) Functional Requirements Standard for Clinical Research](#)  
*Fierce Healthcare: Nov 12 2009 4:43PM Matching: s*

#### Gador S.A. Patents:



- 7560490- [Composition comprising bisphosphonates for prevention and/or treatment of metabolic diseases of bones, process for preparing such composition and use thereof](#)
- 7345183- [Process for obtaining norelgestromin in different relations of isomers E and Z](#)
- 6864228- [Use of bisphosphonates for the treatment of osteogenesis imperfecta](#)
- 6605603- [Uses of 1-amino-3-\(N,N-dimethylamino\)-propylidene-1,1-bisphosphonic acid](#)
- 5990098- [Therapeutic use of 1-amino-3-\(N,N-dimethylamino\)-propylidene-1,1-bisphosphonic acid and its salts](#)
- 5885973- [Bone mass anabolic composition comprising olpadronate](#)

## BioCorporate Profiles - upgrade to a full profile

BioPortfolio's BioCorporate full profiles offers your organization the opportunity to increase internet traffic to your corporate web site and enhance awareness of your business, technology, products and services. BioCorporate profiles are dynamic and are updated weekly with new information sourced from core information resources: publications, clinical trials, patents and global news.

Why you should upgrade your BioPortfolio BioCorporate profile:

- the ability to amend and add information on products and services to your profile using a membership username and password

- the option to add a corporate logo
- the creation of high value URL links back to your organization's website which will improve search engine ranking - resulting in increased site traffic
- the option have your press releases published on BioPortfolio and distributed via our BioNewsCast service
- an enhanced BioCorporate profile will also improve your exposure on BioPortfolio's related service InDepth and GeneDB

The annual cost is \$995.00 for established organizations and \$495.00 for organizations less than 12 months old.

\*\*\*

Resources from the [NCBI](#) used in this document, [NCBI's standard disclaimer applies](#).

Nothing in this document should be used in place of personal medical advice from your own qualified medical practitioner. See BioPortfolio.com [User Agreement](#)

Send comments and feedback to:

Peter Barfoot Managing Director, BioPortfolio Ltd.

UK Tel: (+44) 1300 321501

USA Voicemail and Fax: (+1) 415 680 2472

[Peter Barfoot peter.barfoot@bioportfolio.com](mailto:peter.barfoot@bioportfolio.com)

All rights reserved. All other trademarks recognized.

BioPortfolio Limited is registered in England & Wales at Stafford House, 10 Prince of Wales Road, Dorchester, Dorset, DT1 1PW, UK. No.3312883 VAT No. GB 744 6483 10

Copyright 1997-2009 - BioPortfolio Limited.

